NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $303.59 +7.67 (+2.59%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$284.00 -19.59 (-6.45%) As of 06/26/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ligand Pharmaceuticals Stock (NASDAQ:LGND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$286.00▼$305.7150-Day Range$207.78▼$303.5952-Week Range$111.71▼$305.71Volume1.25 million shsAverage Volume398,062 shsMarket Capitalization$6.08 billionP/E Ratio41.19Dividend YieldN/APrice Target$257.71Consensus RatingModerate Buy Company Overview Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas. The company’s product offerings center around several core platforms. Captisol® is a chemically modified cyclodextrin used to improve the solubility, stability and delivery of small-molecule drug candidates. Ligand’s research services portfolio includes antibody discovery and optimization through its OmniAb™ platform, as well as absorption, distribution, metabolism and excretion (ADME) testing services provided by its Cyprotex and Absorption Systems subsidiaries. Together, these technologies and services support early- and late-stage drug development programs for a broad range of partners worldwide. Founded in 1987 and headquartered in San Diego, California, Ligand has grown through strategic acquisitions and collaborations, establishing a global footprint that spans North America, Europe and Asia. The company’s leadership team is led by President and Chief Executive Officer John L. Higgins, whose experience in drug development and corporate transactions has guided Ligand’s transformation into a technology-focused partner for the biopharmaceutical industry. Ligand continues to seek new alliances and in-licensing opportunities aimed at expanding its platform capabilities and royalty revenue streams.AI Generated. May Contain Errors. Read More Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreLGND MarketRank™: Ligand Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 591st out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingModerate Buy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and no sell ratings.Downside RiskLigand Pharmaceuticals has a consensus price target of $257.71, representing about 15.1% downside from its current price of $303.59.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth94.82% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 94.82% in the coming year, from $4.25 to $8.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 41.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 41.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.87.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 3.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.07% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 8.33.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 3.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentLigand Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,553,493.00 in company stock.Percentage Held by Insiders7.00% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGND Stock News HeadlinesLigand Announces Closing of Convertible Senior Notes OfferingJune 25 at 4:01 PM | globenewswire.comLigand Pharmaceuticals Rises After Upsized Convertible Notes Pricing and Buyback PlanJune 23, 2026 | quiverquant.comQCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.June 27 at 1:00 AM | Paradigm Press (Ad)Ligand Pharmaceuticals prices $625M convertible debt offeringJune 23, 2026 | msn.comLigand Pharmaceuticals (NASDAQ:LGND) Director Stephen Sabba Sells 2,145 Shares of StockJune 19, 2026 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director Sells $1,651,302.38 in StockJune 16, 2026 | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 500 Shares of StockJune 13, 2026 | insidertrades.comAndrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockJune 3, 2026 | insidertrades.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $189.07 on January 1st, 2026. Since then, LGND shares have increased by 60.6% and is now trading at $303.59. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Thursday, May, 7th. The biotechnology company reported $1.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.84 by $0.21. The business's revenue was up 14.1% compared to the same quarter last year. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Top institutional shareholders of Ligand Pharmaceuticals include Janus Henderson Group PLC (5.04%), Stephens Investment Management Group LLC (2.47%), Dimensional Fund Advisors LP (2.12%) and Rice Hall James & Associates LLC (1.42%). Insiders that own company stock include Todd C Davis, Matthew E Korenberg, John W Kozarich, Andrew Reardon, Stephen L Sabba, John L Lamattina, Octavio Espinoza and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/07/2026Today6/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 LGND's financial health is in the Green zone, according to TradeSmith. LGND has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees80Year Founded1987Price Target and Rating Average Price Target for Ligand Pharmaceuticals$257.71 High Price Target$289.00 Low Price Target$220.00 Potential Upside/Downside-15.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$7.37 Trailing P/E Ratio41.19 Forward P/E Ratio71.43 P/E Growth3.31Net Income$124.45 million Net Margins55.95% Pretax Margin67.36% Return on Equity16.19% Return on Assets11.13% Debt Debt-to-Equity Ratio0.45 Current Ratio21.28 Quick Ratio20.95 Sales & Book Value Annual Sales$274.48 million Price / Sales22.17 Cash Flow$8.05 per share Price / Cash Flow37.69 Book Value$51.68 per share Price / Book5.87Miscellaneous Outstanding Shares20,041,000Free Float18,638,000Market Cap$6.08 billion OptionableOptionable Beta1.17 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LGND) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
